CONTRAFECT CORPORATION
CONTRAFECT CORPORATION is a federal contractor, registered under UEI LXUZL23QTTZ9 and CAGE code 661G8. It has been awarded $27,748,714 across 7 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology) and Unknown NAICS. Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Department Of Health And Human Services (hhs).
Contact Information
Registration and classification details
Registration
UEI Code
LXUZL23QTTZ9CAGE Code
661G8Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
Contrafect Corporation specializes in advanced biomedical research and development, with a focus on novel antimicrobial therapies and infectious disease countermeasures. Leveraging deep expertise in microbiology, molecular diagnostics, and therapeutic protein engineering, the company develops precis...
Contrafect Corporation specializes in advanced biomedical research and development, with a focus on novel antimicrobial therapies and infectious disease countermeasures. Leveraging deep expertise in microbiology, molecular diagnostics, and therapeutic protein engineering, the company develops precision antimicrobial agents designed to combat multidrug-resistant pathogens. Their technical capabilities include target identification, high-throughput screening, preclinical validation, and formulation science for next-generation antibacterials and antivirals. Contrafect differentiates itself through its proprietary platform technologies that enable rapid discovery and optimization of biologically active compounds with reduced resistance potential, positioning them at the intersection of translational science and national biosecurity preparedness. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal collaboration can be inferred from the provided data. Consequently, no agency-specific project types or relationship dynamics can be described. The primary NAICS code 541714 indicates that Contrafect operates within scientific research and development in the life sciences, specifically in biomedical research excluding clinical trials. In practice, this means the company is engaged in early-stage therapeutic innovation, laboratory-based discovery, and preclinical development of medical countermeasures. Their market positioning aligns with government-funded initiatives focused on pandemic preparedness, biodefense, and antimicrobial resistance mitigation, serving as a niche R&D provider for public health security priorities. Contrafect Corporation is structured as a small business (2L) headquartered in Yonkers, New York. The company holds no government certifications, and its geographic footprint is limited to its primary location. Without awarded contracts or certifications on record, its government market presence remains unverified, though its technical focus suggests alignment with defense, health, and homeland security research ecosystems.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
